secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-07-13T20:46:20+00:00
Accession:  0001193125-26-302098
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences appoints Steven Hoerter as CEO, John Smither as CFO; CEO Hawryluk departs
--------------------------------------------------------------------------------

- CEO Kent Hawryluk steps down July 13, 2026; will advise through Aug 16, 2026 under consulting agreement.
- Steven Hoerter, former executive Chairman, appointed President and CEO effective July 13, 2026; base salary $665k, target bonus 60%.
- John Smither, interim CFO, appointed CFO effective July 13, 2026; base salary $530k, target bonus 40%, plus $150k relocation bonus.
- New CEO receives 331k stock options and 71k RSUs; new CFO receives 130k options and 28k RSUs, both with 4-year vesting.
- Hawryluk's separation includes 12 months severance, COBRA, target bonus, and accelerated equity vesting through Aug 16, 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526302098/0001193125-26-302098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526302098/d143977d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-302098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer